Physician profile
Jay Stinson
NPI 1528640091
$240.20
in general payments reported to CMS, 2019-2025
8 companies · $14.39 in 2025
The $14.39 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.67 · 2022: $82.28 · 2023: $129 · 2025: $14.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $143.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $66.55 | 2022-2023 | Tezspire |
| Organon LLC | $58.23 | 2021-2023 | Nexplanon |
| Indivior INC. | $29.97 | 2023 | Sublocade |
| Abbvie INC. | $21.96 | 2022 | |
| Exact Sciences Corporation | $18.73 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $15.97 | 2023 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $14.40 | 2023 | Dificid, Zerbaxa, Recarbrio |
| Csl Behring | $14.39 | 2025 | Kcentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Stinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.